الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
When considering the lower SVR rates in insulin-resistant patients insulin-sensitizing agents as adjuvant therapy have been investigated in HCV patients treated with Peg-IFN and ribavirin. (Pierre Deltenre et al., 2011).Stopping rules at weeks 12 and 24 were the first milestones in tailoring therapy. However, predicting who would respond to therapy was a different issue. Clinicians still did not have a reliable predictor of who would respond to therapy if the 12-week and 24-week responses were present and patient was to continue for a total of 48 weeks. Further analysis of the EVR led to a refinement of this definition. (Marcellin et al., 2007).
Our work aimed to evaluate the impact of insulin resistance on early virological response in Egyptian patients with naïve HCV treated with peg interferon and ribavirin and weather prior assessment and treatment of insulin resistance will impact the early treatment response.
We construct a case control, comparative prospective study after screening 266 eligible naïve HCV patients for IR with HOMA-IR test and considered according to previous studies, HOMA level 2 as a cut value for significant IR.